49-534: GSK may refer to: GSK plc , formerly GlaxoSmithKline, a multinational pharmaceutical corporation Galatasaray S.K. , a Turkish sports club based in Istanbul Glycogen synthase kinase Golden State Killer , a California serial rapist and murderer GTK Scene Graph Kit , a rendering pipeline Topics referred to by the same term [REDACTED] This disambiguation page lists articles associated with
98-460: A 10% stake in German biotech company CureVac . In March 2018, GSK announced that it has reached an agreement with Novartis to acquire Novartis's 36.5% stake in their Consumer Healthcare Joint Venture for US$ 13 billion (£9.2 billion). In December 2018, GSK announced that it, along with Pfizer , had reached an agreement to merge and combine their consumer healthcare divisions into
147-579: A German biotech company, for US$ 98 million, and in June, worldwide rights to alitretinoin (Toctino), an eczema drug, for US$ 302 million. In 2013, GSK acquired Human Genome Sciences (HGS) for US$ 3 billion; the companies had collaborated on developing the lupus drug Belimumab (Benlysta), albiglutide for type 2 diabetes , and darapladib for atherosclerosis , and in September, sold its beverage division to Suntory . This included
196-518: A Medicines Research Centre in Stevenage , Hertfordshire . Also that year, Glaxo Wellcome acquired the California -based Affymax, a leader in the field of combinatorial chemistry . By 1999, Glaxo Wellcome had become the world's third-largest pharmaceutical company by revenues (behind Novartis and Merck), with a global market share of around 4 per cent. Its products included Imigran (for
245-684: A Swiss pharmaceutical company, for US$ 190 million, and in June that year that it would sell two meningitis drugs to Pfizer , Nimenrix and Mencevax for around US$ 130 million. Philip Hampton , at that time chair of the Royal Bank of Scotland , became GSK chairman in September 2015. On 31 March 2017, Emma Walmsley became CEO . She is the first female CEO of the company. In December 2017, Reuters reported that Glaxo had increased its stake in its Saudi Arabian unit to 75% (from 49%) taking over control from its Saudi partner Banaja KSA Holding Company. With respect to rare diseases ,
294-803: A US subsidiary of Novartis AG, reaches settlement agreement with US Attorney's Office" . novartis.com. 30 September 2010. Archived from the original on 17 October 2013 . Retrieved 25 August 2012 . ^ Petersen, Melody (21 June 2003). "AstraZeneca Pleads Guilty In Cancer Medicine Scheme" . nytimes.com . Retrieved 25 August 2012 . ^ "Schering-Plough to Pay $ 345 Million to Resolve Criminal and Civil Liabilities for Illegal Marketing of Claritin" . justice.gov. 30 July 2004 . Retrieved 25 August 2012 . Retrieved from " https://en.wikipedia.org/w/index.php?title=List_of_largest_pharmaceutical_settlements&oldid=1254597251 " Categories : Product liability Lists of lawsuits Medical controversies Pharmaceutical industry in
343-510: A US$ 660-million deal, Prestige Brands Holdings took over 17 GSK brands with sales of US$ 210 million, including BC Powder , Beano , Ecotrin , Fiber Choice, Goody's Powder , Sominex and Tagamet . In 2012, the company announced that it would invest £500 million in manufacturing facilities in Ulverston , northern England, designating it as the site for a previously announced biotech plant. In May that year it acquired CellZome,
392-771: A business doing research into animal health, and Recherche et Industrie Thérapeutiques in Belgium in 1963, to focus on vaccines. The company began to expand globally, buying seven laboratories in Canada and the United States in 1969. In 1982, it bought Allergan , a manufacturer of eye and skincare products. Smith Kline & French merged with Beckman Inc. in 1982, and changed its name to SmithKline Beckman . In 1988, it bought International Clinical Laboratories. In 1989, SmithKline Beckman merged with Beecham Group to form SmithKline Beecham P.L.C. . The headquarters moved from
441-425: A demerger and subsequent listing of the joint venture. This will create two publicly traded companies, one focusing on pharmaceuticals and research & development, the other on consumer healthcare. On 22 February 2022, GSK announced that the spin-off consumer healthcare company will be called Haleon . In January 2022, the company announced that they had received three unsolicited offers from Unilever to acquire
490-511: A number of tranches. The same day, the company also announced it would acquire oncology specialist, Tesaro , for US$ 5.1 billion. The deal will give GSK control of ovarian cancer treatment, Zejula - a member of the class of poly ADP ribose polymerase (PARP) inhibitors. In October 2019, GSK agreed to sell its rabies vaccine, RabAvert , and its tick-borne encephalitis vaccine, Encepur , to Bavarian Nordic for US$ 1.06 billion (€955 million). In July 2020, GSK acquired
539-608: A primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index . As of February 2024, it had a market capitalisation of £69 billion, the eighth largest on the London Stock Exchange. The company developed the first malaria vaccine , RTS,S , which it said in 2014, it would make available for five per cent above cost. Legacy products developed at GSK include several listed in
SECTION 10
#1732783671033588-661: A single entity. The combined entity would have sales of around £9.8 billion ($ 12.7 billion), with GSK maintaining a 68% controlling stake in the joint venture. Pfizer would own the remaining 32% shareholding. The deal builds on an earlier 2018 deal where GSK bought out Novartis' stake in the GSK-Novartis consumer healthcare joint business. The culmination of the Consumer Healthcare string of deals will result in GSK splitting into two separate companies, via
637-704: Is a British multinational pharmaceutical and biotechnology company with headquarters in London . It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. GSK is the tenth largest pharmaceutical company and No. 294 on the 2022 Fortune Global 500 , ranked behind other pharmaceutical companies China Resources , Sinopharm , Johnson & Johnson , Pfizer , Roche , AbbVie , Novartis , Bayer , and Merck Sharp & Dohme . The company has
686-679: Is the United States. Its US headquarters are in Philadelphia, Pennsylvania and Durham, North Carolina; its consumer-products division is in Moon Township, Pennsylvania . In July 2020, the UK government signed up for 60 million doses of a COVID-19 vaccine developed by GSK and Sanofi . It uses a recombinant protein –based technology from Sanofi and GSK's pandemic technology. The companies claimed to be able to produce one billion doses, subject to successful trials and regulatory approval, during
735-741: The Beecham Group . In 1859, Beecham opened its first factory in St Helens , Lancashire . By the 1960s, Beecham was extensively involved in pharmaceuticals and consumer products such as Macleans toothpaste , Lucozade and synthetic penicillin research. John K. Smith opened his first pharmacy in Philadelphia in 1830. In 1865, Mahlon Kline joined the business, which 10 years later became Smith, Kline & Co. In 1891, it merged with French, Richard and Company, and in 1929, changed its name to Smith Kline & French Laboratories as it focused more on research. Years later it bought Norden Laboratories,
784-747: The Lucozade and Ribena brands of soft drinks, but they were sold in 2013, to Suntory for £1.35bn. Other products include Abreva to treat cold sores; Night Nurse, a cold remedy; Breathe Right nasal strips ; and Nicoderm and Nicorette nicotine replacements. In March 2014, it recalled Alli , an over-the-counter weight-loss drug, in the United States and Puerto Rico because of possible tampering, following customer complaints. As of 2013 , GSK had offices in over 115 countries and employed over 99,000 people, 12,500 in R&;D . The company's single largest market
833-1479: The Medicaid Drug Rebate Program EpiPen ( epinephrine ) False Claims Act 2006 Schering-Plough $ 435 million Off-label promotion, kickbacks, Medicare fraud Temodar , Intron A , K-Dur , Claritin RediTabs False Claims Act, FDCA 2004 Pfizer $ 430 million Off-label promotion Neurontin False Claims Act, FDCA 2008 Cephalon $ 425 million Off-label promotion Actiq , Gabitril , Provigil False Claims Act, FDCA 2010 Novartis $ 423 million Off-label promotion, kickbacks Trileptal False Claims Act, FDCA 2003 AstraZeneca $ 355 million Medicare fraud Zoladex Prescription Drug Marketing Act 2004 Schering-Plough $ 345 million Medicare fraud, kickbacks Claritin False Claims Act, Anti-Kickback Statute See also [ edit ] Vaccine hesitancy Pharmaceutical fraud List of off-label promotion pharmaceutical settlements References [ edit ] ^ "GlaxoSmithKline to Plead Guilty and Pay $ 3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data" . justice.gov. 2 July 2012. Archived from
882-542: The United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine. Glaxo's $ 3 billion settlement included the largest civil False Claims Act settlement on record, and Pfizer’s $ 2.3 billion ($ 3.5 billion in 2022) settlement including a record-breaking $ 1.3 billion criminal fine. Legal claims against
931-678: The World Health Organization's List of Essential Medicines , such as amoxicillin , mercaptopurine , pyrimethamine and zidovudine . In 2012, under prosecution by the United States Department of Justice (DoJ) based on combined investigations of the Department of Health and Human Services (HHS-OIG), FDA and FBI , primarily concerning sales and marketing of the drugs Avandia , Paxil and Wellbutrin , GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data and kickbacks to physicians in
980-729: The Consumer Healthcare business unit, with the final proposal valuing the business unit at £50 billion (£41.7 billion in cash, plus £8.3 billion in Unilever shares). Subsequently, GSK declined all outside offers/attempts to acquire its consumer healthcare business and moved forward with its plan to complete the demerger from the main biopharmaceutical business. In April 2022, the business announced it would acquire Sierra Oncology Inc for $ 1.9 billion ($ 55 per share). In May 2022, GSK announced it would acquire Affinivax and its phase II 24-valent pneumococcal vaccine candidate for up to $ 3.3 billion, strengthening its vaccine business. On 16 May 2022,
1029-689: The FDA approved GSK's vaccine for 2009 H1N1 influenza protection, manufactured by the company's ID Biomedical Corp in Canada. Also in November 2009, GSK formed a joint venture with Pfizer to create ViiV Healthcare , which specializes in HIV research. In 2010, the company acquired Laboratorios Phoenix, an Argentine pharmaceutical company, for US$ 253m, and the UK-based sports nutrition company Maxinutrition for £162 million (US$ 256 million). In 2011, in
SECTION 20
#17327836710331078-586: The Global Access to Medicines Index, which is funded by the Bill and Melinda Gates Foundation . In 2014, the Human Rights Campaign , an LGBT -rights advocacy group gave GSK a score of 100 per cent in its Corporate Equality Index . List of largest pharmaceutical settlements The following is a list of the 20 largest settlements reached between
1127-1266: The Illegal Marketing of AIDS Drug" . justice.gov. 17 October 2005. Archived from the original on 2 November 2013 . Retrieved 25 August 2012 . ^ "Merck to Pay More than $ 650 Million to Resolve Claims of Fraudulent Price Reporting and Kickbacks" . justice.gov. 7 February 2008 . Retrieved 25 August 2012 . ^ "Office of the Deputy Attorney General" (PDF) . justice.gov. 7 November 2008 . Retrieved 25 August 2012 . ^ "Allergan Agrees to Plead Guilty and Pay $ 600 Million to Resolve Allegations of Off-Label Promotion of Botox®" . justice.gov. 1 September 2010 . Retrieved 25 August 2012 . ^ "Pharmaceutical Giant AstraZeneca to Pay $ 520 Million for Off-label Drug Marketing" . justice.gov. 27 April 2010 . Retrieved 25 August 2012 . ^ "Bristol-Myers Squibb to Pay More Than $ 515 Million to Resolve Allegations of Illegal Drug Marketing and Pricing" . justice.gov. 28 September 2007 . Retrieved 25 August 2012 . ^ "$ 500 million fine for Schering-Plough" . The Philadelphia Inquirer . 18 May 2002. Archived from
1176-636: The US headquarters until the company moved to Research Triangle Park in North Carolina in 1971. The Nobel Prize winning scientists Gertrude B. Elion and George H. Hitchings worked there and invented drugs still used many years later, such as mercaptopurine . In 1959, the Wellcome Foundation bought Cooper, McDougall & Robertson Inc to become more active in animal health. When Burroughs Wellcome decided to move its headquarters,
1225-717: The US market. In 1983, the American arm, Glaxo Inc., moved to Research Triangle Park (US headquarters/research) and Zebulon (US manufacturing) in North Carolina . Burroughs Wellcome & Company was founded in 1880, in London by the American pharmacists Henry Wellcome and Silas Burroughs . The Wellcome Tropical Research Laboratories opened in 1902. In the 1920s, Burroughs Wellcome established research and manufacturing facilities in Tuckahoe, New York , which served as
1274-538: The United States and agreed to pay a US$ 3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in the US and the largest settlement in the pharmaceutical industry . Joseph Nathan and Co. was founded in 1873, as a general trading company in Wellington , New Zealand, by a Londoner, Joseph Edward Nathan . In 1904, it began producing a dried-milk baby food from excess milk produced on dairy farms near Bunnythorpe . The resulting product
1323-635: The United States to England. To expand R&D in the United States, the company bought a new research center in 1995; another opened in 1997, in England at New Frontiers Science Park , Harlow . Glaxo Wellcome and SmithKline Beecham announced their intention to merge in January 2000. The merger was completed on 27 December that year, forming GlaxoSmithKline (GSK). The company's global headquarters were at GSK House, Brentford , London, officially opened in 2002, by then-Prime Minister Tony Blair . The building
1372-518: The brands Lucozade and Ribena ; however, the deal did not include Horlicks . In March 2014, GSK paid US$ 1 billion to raise its stake in its Indian pharmaceutical unit, GlaxoSmithKline Pharmaceuticals , to 75 per cent as part of a move to focus on emerging markets. In April 2014, Novartis and Glaxo agreed on more than US$ 20 billion in deals, with Novartis selling its vaccine business to GSK and buying GSK's cancer business. In February 2015, GSK announced that it would acquire GlycoVaxyn,
1421-658: The business unit as they look to strengthen their presence in India. On 3 December 2018, GSK announced that Unilever would acquire the Indian-listed GlaxoSmithKline Consumer Healthcare business for US$ 3.8 billion (£2.98 billion). Unilever will pay the majority of the deal in cash, with the remaining being paid in shares in its Indian operation, Hindustan Unilever Limited . Upon completion, GSK will then own around 5.7% of Hindustan Unilever Limited, selling those shares in
1470-643: The company aligned with GSK's business. In September 2019, Avalon Ventures announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. This includes its transglutaminase 2 (TG2) small molecule program for the treatment of celiac disease . Four GlaxoSmithKline scientists have been recognized by the Nobel Committee for their contributions to basic medical science and/or therapeutics development. Since 2010, GlaxoSmithKline has several times ranked first among pharmaceutical companies on
1519-1312: The company changed its name from GlaxoSmithKline to GSK. In April 2023, GSK announced it would acquire Bellus Health Inc. for $ 2 billion. In February 2024, the company acquired Aiolos Bio for over $ 1 billion, adding to its existing asthma business through AIO-001 a long-acting monoclonal antibody that targets the thymic stromal lymphopoietin cytokine. In May 2024, GSK sold off its 4.2% shares in Haleon for $ 1.58 billion. In July 2024, GSK moved its headquarters from Brentford to New Oxford Street in central London. GSK manufactures products for major disease areas such as asthma, cancer, infections, diabetes, and mental health. Medicines historically discovered or developed at GSK and its legacy companies and now sold as generics include amoxicillin and amoxicillin-clavulanate , ticarcillin-clavulanate , mupirocin , and ceftazidime for bacterial infections, zidovudine for HIV infection , valacyclovir for herpes virus infections, albendazole for parasitic infections, sumatriptan for migraine , lamotrigine for epilepsy, bupropion and paroxetine for major depressive disorder , cimetidine and ranitidine for gastroesophageal reflux disorder , mercaptopurine and thioguanine for
GSK - Misplaced Pages Continue
1568-456: The company divested its portfolio of gene therapy drugs to Orchard Therapeutics in April 2018. In November 2018, Reuters reported that Unilever was in prime position to acquire GSK's interest in its Indian unit, GlaxoSmithKline Consumer Healthcare Ltd, in a sale that could generate around US$ 4 billion for the company. Nestlé and Coca-Cola have also been reported to be interested in
1617-517: The company selected Paul Rudolph to design its new building. The Elion-Hitchings Building "was celebrated worldwide when it was built," according to Paul Rudolph Heritage Foundation president Kelvin Dickinson. Alex Sayf Cummings of Georgia State University wrote in 2016, that the "iconic building helped define the image of RTP," saying, "Love it or hate it, Rudolph's design remains an impressively audacious creative gesture and an important part of
1666-551: The first malaria vaccine . Malaria is responsible for over 650,000 deaths annually, mainly in Africa. Known as RTS,S , the vaccine was developed as a joint project with the PATH vaccines initiative and the Bill and Melinda Gates Foundation . The company has committed to making the vaccine available in developing countries for five per cent above the cost of production. As of 2013 , RTS,S, which uses GSK's proprietary AS01 adjuvant,
1715-496: The first half of 2021. The company also agreed to a $ 2.1 billion deal with the United States to produce 100 million doses of the vaccine. SR One was established in 1985, by SmithKline Beecham to invest in new biotechnology companies and continued operating after GSK was formed; by 2003, GSK had formed another subsidiary, GSK Ventures, to out-license or start new companies around drug candidates that it did not intend to develop further. As of 2003 , SR One tended to invest only if
1764-457: The group's structure in 1947, making Glaxo the parent and obtained a listing on the London Stock Exchange . Glaxo acquired Allen & Hanburys in 1958. The Scottish pharmacologist David Jack was hired as a researcher for Allen & Hanburys a few years after Glaxo took it over; he went on to lead the company's research and development (R&D) until 1987. After Glaxo bought Meyer Laboratories in 1978, it began to play an important role in
1813-515: The history of both architecture and Research Triangle Park ." United Therapeutics , which bought the building in 2012, announced plans in 2020, to tear it down. Glaxo and Wellcome merged in 1995, to form Glaxo Wellcome plc. The merger was then considered the biggest in the UK corporate history. Glaxo Wellcome restructured its R&D operation that year, cutting 10,000 jobs worldwide, closing its R&D facility in Beckenham, Kent, and opening
1862-987: The original on January 1, 2014 . Retrieved 25 August 2012 . ^ Mole, Beth (October 7, 2016). "For ripping off Medicaid, EpiPen maker Mylan pays Feds $ 465 million" . Ars Technica . Retrieved December 3, 2016 . ^ "Schering to Pay $ 435 Million for the Improper Marketing of Drugs and Medicaid Fraud" (PDF) . justice.gov. 29 August 2006 . Retrieved 25 August 2012 . ^ "Warner-Lambert to Pay $ 430 Million to Resolve Criminal & Civil Health Care Liability Relating to Off-Label Promotion" . usdoj.gov . United States Department of Justice. 13 May 2004 . Retrieved 30 July 2017 . ^ "Biopharmaceutical Company, Cephalon, to Pay $ 425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing" . U.S. Department of Justice . 29 September 2008 . Retrieved 30 July 2017 . ^ "Novartis Pharmaceuticals Corporation,
1911-2358: The original on 2024-07-14 . Retrieved 25 August 2012 . ^ "Justice Department Announces Largest Health Care Fraud Settlement in Its History" . justice.gov. 2 September 2009 . Retrieved 12 June 2024 . ^ Almashat, S et al . Rapidly Increasing Criminal and Civil Monetary Penalties Against the Pharmaceutical Industry: 1991 – 2010 . Public Citizen’s Health Research Group. December 16, 2010 ^ Katie Thomas, Michael S. Schmidt (2 July 2012). "Glaxo Agrees to Pay $ 3 Billion in Fraud Settlement" . The New York Times . Retrieved 25 August 2012 . ^ Lavoie, Denise (5 December 2007). "Drug Whistleblower Collects $ 24M" . cbsnews.com . Retrieved 25 August 2012 . ^ formed in 2000 by merger of Glaxo Wellcome and SmithKline Beecham ^ "Johnson & Johnson to Pay More Than $ 2.2 Billion to Resolve Criminal and Civil Investigations" . justice.gov. 4 November 2013 . Retrieved 5 March 2015 . ^ "Abbott Labs to Pay $ 1.5 Billion to Resolve Criminal & Civil Investigations of Off-label Promotion of Depakote" . justice.gov. 7 May 2012 . Retrieved 25 August 2012 . ^ "Eli Lilly and Company Agrees to Pay $ 1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa" . justice.gov. 15 January 2009 . Retrieved 25 August 2012 . ^ "TAP Pharmaceutical Products Inc. and Seven Others Charged with Health Care Crimes; Company Agrees to Pay $ 875 Million to Settle Charges" . justice.gov. 3 October 2001 . Retrieved 25 August 2012 . ^ "Amgen Inc. Pleads Guilty to Federal Charge in Brooklyn, NY.; Pays $ 762 Million to Resolve Criminal Liability and False Claims Act Allegations" . justice.gov. 19 December 2012 . Retrieved 20 December 2012 . ^ "GlaxoSmithKline to Plead Guilty & Pay $ 750 Million to Resolve Criminal and Civil Liability Regarding Manufacturing Deficiencies at Puerto Rico Plant" . justice.gov. 26 October 2010 . Retrieved 25 August 2012 . ^ "Serono to Pay $ 704 Million for
1960-875: The pharmaceutical industry have varied widely over the past two decades, including Medicare and Medicaid fraud , off-label promotion, and inadequate manufacturing practices. With respect to off-label promotion, specifically, a federal court recognized off-label promotion as a violation of the False Claims Act for the first time in Franklin v. Parke-Davis , leading to a $ 430 million settlement. Year Company Settlement Violation(s) Product(s) Laws violated (if applicable) 2012 GlaxoSmithKline $ 3 billion ($ 1B criminal, $ 2B civil) Criminal: Off-label promotion, failure to disclose safety data. Civil: paying kickbacks to physicians, making false and misleading statements concerning
2009-2502: The safety of Avandia, reporting false best prices and underpaying rebates owed under the Medicaid Drug Rebate Program Avandia (not providing safety data), Wellbutrin , Paxil (promotion of paediatric use), Advair , Lamictal , Zofran , Imitrex , Lotronex , Flovent , Valtrex False Claims Act , FDCA 2009 Pfizer $ 2.3 billion Off-label promotion, kickbacks Bextra , Geodon , Zyvox , Lyrica False Claims Act, FDCA 2013 Johnson & Johnson $ 2.2 billion Off-label promotion, kickbacks Risperdal , Invega , Nesiritide False Claims Act, FDCA 2012 Abbott Laboratories $ 1.5 billion Off-label promotion Depakote False Claims Act, FDCA 2009 Eli Lilly $ 1.4 billion Off-label promotion Zyprexa False Claims Act, FDCA 2001 TAP Pharmaceutical Products $ 875 million Medicare fraud , kickbacks Lupron False Claims Act, Prescription Drug Marketing Act 2012 Amgen $ 762 million Off-label promotion, kickbacks Aranesp False Claims Act, FDCA 2010 GlaxoSmithKline $ 750 million Poor manufacturing practices Kytril , Bactroban , Paxil CR , Avandamet False Claims Act, FDCA 2005 Serono $ 704 million Off-label promotion, kickbacks, monopolistic practices Serostim False Claims Act 2008 Merck $ 650 million Medicare fraud, kickbacks Zocor , Vioxx , Pepsid False Claims Act, Medicaid Rebate Statute 2007 Purdue Pharma $ 601 million Off-label promotion Oxycontin False Claims Act 2010 Allergan $ 600 million Off-label promotion Botox False Claims Act, FDCA 2010 AstraZeneca $ 520 million Off-label promotion, kickbacks Seroquel False Claims Act 2007 Bristol-Myers Squibb $ 515 million Off-label promotion, kickbacks, Medicare fraud Abilify , Serzone False Claims Act, FDCA 2002 Schering-Plough $ 500 million Poor manufacturing practices Claritin FDA Current Good Manufacturing Practices 2006 Mylan $ 465 million Misclassification under
GSK - Misplaced Pages Continue
2058-499: The title GSK . If an internal link led you here, you may wish to change the link to point directly to the intended article. Retrieved from " https://en.wikipedia.org/w/index.php?title=GSK&oldid=1246647665 " Category : Disambiguation pages Hidden categories: Short description is different from Wikidata All article disambiguation pages All disambiguation pages GSK plc GSK plc (an acronym from its former name GlaxoSmithKline plc )
2107-421: The treatment of leukemia, allopurinol for gout , pyrimethamine for malaria , and the antibacterial trimethoprim . Among these, albendazole, amoxicillin, amoxicillin-clavulanate, allopurinol, mercaptopurine, mupirocin, pyrimethamine, ranitidine, thioguanine, trimethoprim, and zidovudine are on the World Health Organization's List of Essential Medicines . In 2014, GSK applied for regulatory approval for
2156-455: The treatment of migraine), salbutamol (Ventolin) (for the treatment of asthma), Zovirax (for the treatment of coldsores), and Retrovir and Epivir (for the treatment of AIDS). In 1999, the company was the world's largest manufacturer of drugs for the treatment of asthma and HIV/AIDS. It employed 59,000 people, including 13,400 in the UK, had 76 operating companies and 50 manufacturing facilities worldwide, and seven of its products were among
2205-579: The world's top 50 best-selling pharmaceuticals. The company had R&D facilities in Hertfordshire, Kent , London and Verona (Italy), and manufacturing plants in Scotland and the north of England. It had R&D centres in the US and Japan, and production facilities in the US, Europe and the Far East. In 1848, Thomas Beecham launched his Beecham's Pills laxative in England, giving birth to
2254-578: Was appointed chairman of the board in 2005. GSK opened its first R&D centre in China in 2007, in Shanghai, initially focused on neurodegenerative diseases. Andrew Witty became the chief executive officer in 2008. Witty joined Glaxo in 1985, and had been president of GSK's Pharmaceuticals Europe since 2003. In 2009, GSK acquired Stiefel Laboratories , then the world's largest independent dermatology drug company, for US$ 3.6 billion . In November 2009,
2303-756: Was being examined in a Phase 3 trial in eight African countries. PATH reported that "[i]n the 12-month period following vaccination, RTS,S conferred approximately 50% protection from clinical Plasmodium falciparum disease in children aged 5-17 months, and approximately 30% protection in children aged 6-12 weeks when administered in conjunction with Expanded Program for Immunization (EPI) vaccines." In 2014, Glaxo said it had spent more than US$ 350 million and expected to spend an additional US$ 260 million before seeking regulatory approval. GSK's consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare, including Aquafresh , Macleans and Sensodyne toothpastes. GSK also previously owned
2352-498: Was erected at a cost of £300 million and as of 2002 was home to 3,000 administrative staff. GSK completed the acquisition of New Jersey–based Block Drug in 2001, for US$ 1.24 billion . In 2006, GSK acquired the US-based consumer healthcare company CNS Inc., whose products included Breathe Right nasal strips and FiberChoice dietary supplements, for US$ 566 million in cash. Chris Gent , previously CEO of Vodafone ,
2401-441: Was first known as Defiance, then as Glaxo (from lacto ), and sold with the slogan "Glaxo builds bonnie babies." The Glaxo Laboratories sign is still visible on what is now a car repair shop on the main street of Bunnythorpe. The company's first pharmaceutical product, released in 1924, was vitamin D. Glaxo Laboratories was incorporated as a distinct subsidiary company in London in 1935. Joseph Nathan's shareholders reorganised
#32967